Clinical Study of PET/CT and Association With Metabolic Syndrome/Depressive Symptoms in Psoriasis

Phase 0 Clinical Study of PET/CT and Association With Metabolic Syndrome/Depressive Symptoms in Psoriasis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01661127

Enrollment

Registered

2012-08-09

Start date

2012-06-30

Completion date

2015-12-31

Last updated

2014-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Metabolic Syndrome, Psoriasis

Brief summary

Psoriasis is associated with increases in markers of inflammation in the skin and blood and increasingly is thought to be a systemic inflammatory disease and risk factor for incident diabetes mellitus, myocardial infarction, stroke, and premature cardiovascular death. Furthermore, it is important for clinicians to be aware that psoriasis can have a substantial emotional impact on an individual, which is not necessarily related to the extent of skin disease. FDG-PET/CT represents an innovative approach to studying systemic inflammation in a manner that is sensitive, quantifiable, and anatomically localizable. Also, recent study show that chronic disease such as end stage renal disease with depressive symptoms have decreased cerebral glucose metabolism in several brain areas in F-18-FDG PET/CT. So this protocol was designed to evaluate usefulness of PET/CT to detect systemic inflammation and abnormality of cerebral glucose metabolism and association with metabolic syndrome/major depressive symptoms in patients with psoriasis.

Detailed description

10 Patients with psoriasis 1. Evaluate PASI score 2. Evaluate comorbidity with metabolic syndrome * Body mass index(BMI) * Checking blood pressure * Checking blood sugar * Smoking and drinking history * Checking blood cholesterol level * Risk factors of cardiovascular disease 3. PET/CT for measuring the extent and site of psoriasis with inflammation

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histological diagnosis of plaque type psoriasis * at least 18 years old

Exclusion criteria

* those who cannot understand questionnaire * those who take antidepressant

Design outcomes

Primary

Measure	Time frame
Beck depression inventory scoring and Korean Hamilton depression scale scoring	Day 0 and 28 weeks later

Secondary

Measure	Time frame
Brain glucose uptake using PET/CT	Day 0 and 28 weeks later

Countries

South Korea

Contacts

Primary ContactByung-Soo Kim, Ph D.

dockbs@pusan.ac.kr82-51-240-7338

Outcome results